{'fraction_non_alphanumeric': 0.04418145956607495, 'fraction_numerical': 0.04260355029585799, 'mean_word_length': 5.536082474226804, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
AB1115 The Characteristics of Therapy of Patients with Rheumatoid Arthritis in the Russian Federation According to the Russian Register

Background Development of registers of patients is one of the most important directions in studying of rheumatoid arthritis (RA) which can provide unique information. Until recently there was no unified register of patients with RA, but only registers of patients on specific therapies (the largest – the Russian biologics register ARBITER). Objectives To obtain reliable information about the real-world clinical practice in the area of the management of patients with rheumatoid arthritis. Methods The project of All-Russian Register of patients with Rheumatoid Arthritis (ARRRA) started in March, 2012. Due to large number of regions (85) in Russian Federation, and long distances between them, the register was created as internet-based database. Patient population included: patients with RA according to classification criteria (ACR/EULAR 2010 and/or ACR 1987), patients with early RA (including probable RA), adult patients with juvenile arthritis. ARRA database contains the following core information: demographics, classification criteria, comorbidities, RF/ACPA status, joint counts, Indices of activity: DAS28, SDAI, CDAI, PROs: VAS, HAQ, RAPID3, EQ 5D, anti-rheumatic and concomitant medications, serious adverse events, non-pharmacological treatments, orthopedic surgery, employment status. Results 4685 patients included at Nov 2014 from 16 main rheumatology centers, representing 71 regions of Russia. 3670 patients had definite diagnosis of RA (after exclusion of juvenile arthritis and probable RA): 82,6% females, 17,4% males, 74,3% RF positive. Comorbid conditions were listed in 52% of pts, the main conditions were arterial hypertension (39,9%) and IHD (12,5%). At Nov 2014, 89,1% pts received synthetic DMARDs, including 76,1% on methotrexate (MTX), alone or in combination, these proportions was relatively stable since Dec 2012. The proportion of patients being on biological DMARDs increased from 11,4% in Dec 2012 to 21% in Nov 2014. The proportions of patients used oral steroids and NSAIDs decreased from 67,8% and 80,1% to 57,9% and 63,2% respectively. Mean DAS28 score changed during this period from 5.04±1,42 to 3,98±1,31. Conclusions The increased use of methotrexate and biologic DMARDs corresponds to the decrease of disease activity, oral steroids and NSAIDs use in wide population of patients with RA in Russian Federation. Disclosure of Interest None declared